What evidence supports a single 3 g dose of oral glycine taken before bedtime to improve sleep in a healthy adult without renal impairment, pregnancy, lactation, or hypersensitivity?

Glycine 3g for Sleep: Limited Evidence and Not Guideline-Recommended

Glycine 3g before bedtime is not recommended by any major sleep medicine guideline, and the available evidence consists only of small mechanistic studies showing modest improvements in subjective sleep quality and daytime performance after sleep restriction—not robust data for treating insomnia in healthy adults. 1, 2

---

Why Glycine Is Not in Clinical Guidelines

• The American Academy of Sleep Medicine (AASM) and American College of Physicians explicitly recommend against herbal supplements and nutritional substances (including amino acids like glycine) for insomnia due to insufficient evidence of efficacy. 1
• No large-scale randomized controlled trials have evaluated glycine for chronic insomnia, and it does not appear in any FDA-approved treatment algorithms or professional society guidelines for sleep disorders. 1, 2
• The AASM states that over-the-counter supplements lack the quality of evidence required to support clinical use, placing glycine in the same category as valerian and melatonin supplements (which also lack strong efficacy data). 1, 2

---

What the Research Actually Shows

Small Human Studies with Modest Effects

• A 2012 study in Frontiers in Neurology found that 3g glycine before bedtime reduced subjective fatigue and sleepiness the next day in healthy volunteers whose sleep was experimentally restricted by 25%—but this was not a study of people with insomnia, and the primary outcome was daytime performance, not sleep quality itself. 3
• The same research group reported in the Journal of Pharmacological Sciences that glycine ingestion improved subjective sleep quality in individuals with "insomniac tendencies", but the study design, sample size, and diagnostic criteria were not rigorous enough to establish clinical efficacy. 4
• These studies measured subjective sleep quality (self-reported questionnaires), not objective polysomnography (PSG) outcomes like total sleep time, sleep latency, or wake after sleep onset—the gold-standard metrics used in guideline-level evidence. 3, 4

Proposed Mechanism: Hypothermia and NMDA Receptor Modulation

• Animal studies suggest that glycine promotes sleep by lowering core body temperature through peripheral vasodilation, mediated by NMDA receptors in the suprachiasmatic nucleus (SCN) of the hypothalamus. 5
• Glycine may also inhibit orexin (hypocretin) neurons, which are wake-promoting cells in the lateral hypothalamus, via glycine receptor activation. 6
• However, these mechanistic findings in rodents have not been translated into clinically meaningful human trials, and the doses used in animal studies do not directly correspond to the 3g human dose. 5, 6

---

Why This Evidence Is Insufficient for Clinical Use

• The studies are small (n < 50 in most cases), short-duration (single-night or 3-night protocols), and lack placebo-controlled replication in diverse populations. 3, 4
• Subjective sleep quality improvements do not necessarily translate to objective sleep architecture changes (e.g., increased slow-wave sleep, reduced nocturnal awakenings), which are the outcomes that matter for morbidity and quality of life. 3, 4
• No long-term safety data exist for nightly glycine supplementation, and the studies did not assess potential interactions with medications or comorbid conditions. 7
• Glycine did not alter circadian clock gene expression (Bmal1, Per2) or plasma melatonin levels in the one study that measured these outcomes, suggesting its effects are indirect and may not address the underlying pathophysiology of chronic insomnia. 3

---

What You Should Do Instead: Guideline-Recommended Treatments

First-Line: Cognitive Behavioral Therapy for Insomnia (CBT-I)

• The AASM and American College of Physicians issue a strong recommendation that all adults with chronic insomnia receive CBT-I as the initial treatment before any medication, because it provides superior long-term efficacy with sustained benefits after treatment ends. 1, 2
• CBT-I includes stimulus control, sleep restriction, relaxation techniques, and cognitive restructuring, and can be delivered via individual therapy, group sessions, telephone, web-based modules, or self-help books—all formats show effectiveness. 1, 2

First-Line Pharmacotherapy (If CBT-I Is Insufficient)

• For sleep-onset insomnia: Zolpidem 10 mg (5 mg if age ≥65 years), zaleplon 10 mg (5 mg if elderly), or ramelteon 8 mg. 1, 2
• For sleep-maintenance insomnia: Low-dose doxepin 3–6 mg (reduces wake after sleep onset by 22–23 minutes with minimal anticholinergic effects and no abuse potential). 1, 2
• For combined sleep-onset and maintenance insomnia: Eszopiclone 2–3 mg (1 mg if age ≥65 years or hepatic impairment). 1, 2

Agents Explicitly Not Recommended

• Over-the-counter antihistamines (diphenhydramine) lack efficacy data, cause strong anticholinergic effects (confusion, falls, urinary retention), and develop tolerance within 3–4 days. 1, 2
• Trazodone yields only ~10 minutes reduction in sleep latency with no improvement in subjective sleep quality, and adverse events occur in ~75% of older adults. 1, 2
• Melatonin supplements produce only ~9 minutes reduction in sleep latency with insufficient evidence for chronic insomnia. 1, 2
• Herbal supplements (valerian, L-tryptophan) and nutritional substances (including glycine) lack adequate evidence to support use for primary insomnia. 1, 2

---

Common Pitfalls to Avoid

• Using glycine or other unproven supplements instead of evidence-based treatments delays effective therapy and allows insomnia to become chronic, worsening quality of life. 1, 2
• Assuming "natural" supplements are safer than FDA-approved medications ignores the fact that glycine has no long-term safety data, no established dosing guidelines, and no regulatory oversight for purity or potency. 7
• Failing to implement CBT-I before or alongside any pharmacotherapy is the single biggest mistake in insomnia management, as behavioral therapy provides more durable benefits than medication alone. 1, 2

---

Bottom Line

Glycine 3g is not a guideline-recommended treatment for insomnia, and the existing evidence consists only of small, short-term studies showing modest subjective improvements in sleep-restricted volunteers—not clinically meaningful data for treating chronic insomnia. If you have persistent sleep difficulties, start with CBT-I (the gold standard), and if pharmacotherapy is needed, use FDA-approved agents with proven efficacy and safety profiles (e.g., low-dose doxepin, zolpidem, eszopiclone, ramelteon). 1, 2